Literature DB >> 9301630

Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats.

M Kimura1, I Kurose, J Russell, D N Granger.   

Abstract

The overall objective of this study was to determine whether peroral treatment with the 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor fluvastatin influences the leukocyte-endothelial cell adhesion (LECA) observed in postcapillary venules of hypercholesterolemic rats. Rats were fed either normal chow or a chow supplemented with 1% cholesterol for 10 days. Leukocyte adherence and extravasation, leukocyte rolling velocity, red blood cell velocity, and vessel diameter were monitored in mesenteric venules superfused with either 100 nmol/L platelet-activating factor (PAF) or 20 nmol/L leukotriene B4 (LTB4). Hypercholesterolemic rats exhibited an exaggerated LECA response compared with their normocholesterolemic counterparts. In hypercholesterolemic rats, treatment with fluvastatin significantly attenuated the leukocyte-adherence responses to PAF and LTB4 as well as the leukocyte emigration response to LTB4. Fluvastatin treatment also inhibited the PAF- and LTB4-induced reductions in leukocyte rolling velocity. These findings indicate that fluvastatin blunts the inflammatory responses elicited in post-capillary venules by lipid mediators.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9301630     DOI: 10.1161/01.atv.17.8.1521

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  25 in total

1.  HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins.

Authors:  Franz Wiesbauer; Christoph Kaun; Gerlinde Zorn; Gerald Maurer; Kurt Huber; Johann Wojta
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

2.  Do statins afford neuroprotection in patients with cerebral ischaemia and stroke?

Authors:  C J Vaughan; N Delanty; C T Basson
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 3.  Inflammation and lipid-lowering treatment.

Authors:  C M Ballantyne; Y Abe
Journal:  Curr Cardiol Rep       Date:  1999-09       Impact factor: 2.931

Review 4.  Potential therapeutic role for statins in respiratory disease.

Authors:  E Hothersall; C McSharry; N C Thomson
Journal:  Thorax       Date:  2006-08       Impact factor: 9.139

Review 5.  Statin treatment and progression of atherosclerotic plaque burden.

Authors:  Diederick E Grobbee; Michiel L Bots
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 6.  [Statins for treatment of CNS diseases. Status report from research and clinical practice].

Authors:  T Menge; H-C von Büdingen; S S Zamvil; H-P Hartung; B C Kieseier; O Stüve
Journal:  Nervenarzt       Date:  2005-04       Impact factor: 1.214

7.  Diet and age interactions with regards to cholesterol regulation and brain pathogenesis.

Authors:  Romina M Uranga; Jeffrey N Keller
Journal:  Curr Gerontol Geriatr Res       Date:  2010-04-11

8.  Pharmacological characterisation of anti-inflammatory compounds in acute and chronic mouse models of cigarette smoke-induced inflammation.

Authors:  Wing-Yan Heidi Wan; Abigail Morris; Gillian Kinnear; William Pearce; Joanie Mok; Daniel Wyss; Christopher S Stevenson
Journal:  Respir Res       Date:  2010-09-18

9.  Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis.

Authors:  Patrick M Winter; Shelton D Caruthers; Huiying Zhang; Todd A Williams; Samuel A Wickline; Gregory M Lanza
Journal:  JACC Cardiovasc Imaging       Date:  2008-09

10.  Fluvastatin treatment inhibits leucocyte adhesion and extravasation in models of complement-mediated acute inflammation.

Authors:  F Fischetti; R Carretta; G Borotto; P Durigutto; R Bulla; P L Meroni; F Tedesco
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.